THEMISMED132.00

Themis Medicare Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersLINCOLNBAJAJHCARESIGACHIWANBURYAMRUTANJANAHCLANUHPHRMcap ₹1,216 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations104.882.597.8123.0117.093.871.797.678.090.176.587.0
Other Income2.40.61.11.01.11.01.61.23.21.33.71.0
Total Income107.283.198.9124.0118.194.873.398.881.291.480.288.0
Expenses
+ Cost of Materials Consumed26.221.121.723.521.112.819.012.416.114.514.317.6
+ Purchases of Stock-in-Trade13.918.111.816.718.122.516.321.718.211.611.549.8
+ Changes in Inventories1.8-12.85.81.02.5-6.8-14.718.3-10.23.0-2.0-9.5
+ Employee Benefit Expense19.919.922.521.624.425.025.524.824.922.721.122.2
+ Finance Costs2.02.72.22.42.42.82.52.52.82.72.73.0
+ Depreciation & Amortisation3.13.13.12.42.52.52.52.62.62.62.62.5
+ Other Expenses30.628.026.831.033.931.831.430.432.028.528.059.2
Total Expenses97.580.293.798.6104.890.682.5112.786.485.778.1144.9
EBITDA12.48.19.329.217.18.5-5.8-10.1-3.19.83.8-52.4
EBIT9.35.06.226.814.76.0-8.3-12.6-5.77.21.2-55.0
Profit
PBT before Exceptional Items9.72.85.225.413.44.2-9.2-13.9-5.25.72.1-56.9
+ Exceptional Items0.00.00.00.00.00.00.00.00.0-0.90.093.0
Pretax Income9.72.85.225.413.44.2-9.2-13.9-5.24.92.136.0
+ Current Tax2.50.81.86.43.31.2-2.50.00.00.00.08.3
+ Deferred Tax0.20.10.30.30.3-0.01.00.20.20.30.25.7
Tax Expense2.60.92.16.73.51.1-1.50.20.20.30.214.0
+ Share of Associates & JVs4.25.43.66.04.4-2.6-1.9-0.11.75.56.92.6
Net Income11.37.46.624.714.30.5-9.7-14.2-3.610.18.924.6
+ Net Income — Continuing Ops7.12.03.118.79.93.1-7.8-14.1-5.44.62.022.0
+ Other Comprehensive Income-0.1-0.1-0.4-0.20.2-0.0-0.2-0.0-0.1-0.5-0.1-0.2
Total Comprehensive Income11.27.36.224.514.50.5-9.9-14.2-3.79.68.824.4
Net Income to Common11.37.46.624.70.00.5-9.7-14.2-3.610.18.924.6
Minority Interest0.00.0-0.0-0.00.00.0-0.0-0.00.00.0-0.00.0
Per Share
Basic EPS12.300.800.722.681.550.06-1.05-1.54-0.391.100.962.67
Diluted EPS12.280.800.722.681.550.06-1.05-1.54-0.391.090.962.67
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.2-0.0-0.1-0.5-0.1-0.2
+ Items NOT to be Reclassified to P&L-0.1-0.1-0.6-0.20.2-0.0-0.3-0.1-0.1-0.7-0.1-0.2
+ Tax on Items NOT to be Reclassified-0.1-0.0-0.0-0.2-0.0-0.1
+ Tax on Items NOT to be Reclassified — alt tag-0.0-0.0-0.1-0.10.0-0.0
+ Items to be Reclassified to P&L0.0-0.00.00.00.0
+ Tax on Items to be Reclassified0.0-0.00.00.00.0
Comprehensive Income — Owners of Parent11.27.36.224.50.00.5-9.9-0.0-3.79.6-0.124.4
Comprehensive Income — Non-controlling Interests0.00.0-0.0-0.00.00.0-0.00.00.00.00.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations12.300.800.722.681.550.06-1.05-1.54-0.391.100.962.67
Diluted EPS — Continuing Operations12.280.800.722.681.550.06-1.05-1.54-0.391.090.962.67
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit62.856.058.681.775.465.351.145.253.861.052.829.0
Gross Margin %59.9767.9159.9066.4564.4269.6271.2946.3069.0467.6368.9733.32
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)9.72.85.225.413.44.2-9.2-13.9-5.25.72.1-56.9
− Exceptional Items (reconciliation)0.00.00.00.00.00.00.00.00.0-0.90.093.0
Net Income Adj (tax-effected)11.37.46.624.714.30.5-9.7-14.2-3.610.98.9-32.2
EPS Adj12.300.800.722.681.550.06-1.05-1.54-0.391.190.96-3.50
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.001.001.001.001.001.001.00920.4010.00921.001.001.00
Paid Up Equity Capital9.29.29.29.29.29.29.29.29.29.29.29.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.